Experimental cancer pill shows early promise but study halted
NCT ID NCT06270082
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This early-phase study tested an experimental oral drug called IK-595 in 75 adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have specific RAS or RAF gene mutations. The goal was to check safety, find the right dose, and see if it shrinks tumors. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
INOVA Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Johns Hopkins University of Medicine Sidney Kimmel Comprehensive Care Center
Washington D.C., District of Columbia, 20016, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Next Oncology
Austin, Texas, 78758, United States
-
Next Oncology- San Antonio
San Antonio, Texas, 78229, United States
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute at HealthOne
Denver, Colorado, 80218, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of California Irvine
Orange, California, 92868, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Pittsburgh Medical Center- Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.